Vytrus Biotech S.A. Market Cap ($120.39 Million)
Market Cap & Net Worth: Vytrus Biotech S.A. (VYT)
Vytrus Biotech S.A. market cap. Vytrus Biotech S.A. (MC:VYT) has a market capitalization of $120.39 Million (€102.98 Million) as of November 7, 2026. Listed on the MC stock exchange, this Spain-based company holds position #18250 globally and #124 in its home market, demonstrating a -5.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vytrus Biotech S.A.'s stock price €13.70 by its total outstanding shares 7516458 (7.52 Million). Also see Vytrus Biotech S.A. (VYT) cash flow conversion for how efficiently the company converts equity into cash flow.
Vytrus Biotech S.A. Market Cap History (2022–2026)
Vytrus Biotech S.A. market cap history from 2022 to 2026. Data shows growth from $29.88 Million to $120.39 Million (48.78% CAGR). Check VYT share price today for real-time trading data and today's change.
Vytrus Biotech S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vytrus Biotech S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore VYT shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
8.97x
Vytrus Biotech S.A.'s market cap is 8.97 times its annual revenue
Latest Price to Earnings (P/E) Ratio
25.94x
Vytrus Biotech S.A.'s market cap is 25.94 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $29.88 Million | $3.68 Million | $605.26K | 8.11x | 49.36x |
| 2023 | $28.82 Million | $3.74 Million | $544.94K | 7.71x | 52.89x |
| 2024 | $18.98 Million | $5.04 Million | $1.02 Million | 3.76x | 18.59x |
| 2025 | $75.13 Million | $8.37 Million | $2.90 Million | 8.97x | 25.94x |
Competitor Companies of VYT by Market Capitalization
Companies near Vytrus Biotech S.A. in the global market cap rankings as of November 7, 2026. Also see Vytrus Biotech S.A. (VYT) total assets for a full breakdown of the balance sheet.
Key companies related to Vytrus Biotech S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Vytrus Biotech S.A. (2022–2026)
Market capitalization of Vytrus Biotech S.A. from 2022 to today. Between 2022 and today, Vytrus Biotech S.A.'s market cap moved from $29.88 Million to $ 120.39 Million, with a yearly change of 48.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €120.39 Million | +60.23% |
| 2025 | €75.13 Million | +295.83% |
| 2024 | €18.98 Million | -34.15% |
| 2023 | €28.82 Million | -3.53% |
| 2022 | €29.88 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Vytrus Biotech S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $120.39 Million USD |
| MoneyControl | $120.39 Million USD |
| MarketWatch | $120.39 Million USD |
| marketcap.company | $120.39 Million USD |
| Reuters | $120.39 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vytrus Biotech S.A.
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more